Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Economics of Cancer Care
Current Practice Least Cost-Effective Option in Prostate Cancer Management
By
Meg Barbor, MPH
Economics & Value
,
Economics of Cancer Care
October 2015, Vol 6, No 9
Copenhagen, Denmark—Current follow-up strategy for patients with prostate cancer was found to be the least cost-effective approach in an analysis conducted in Europe.
Read Article
Whole-Brain Radiotherapy for Brain Metastases Is Cost-Effective
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
October 2015, Vol 6, No 9
The treatment of patients with brain metastases involves issues of controlling recurrence, side effects, and costs.
Read Article
Patients with Cancer Eager to Discuss Costs of Care with Their Oncologists
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
September 2015, Vol 6, No 8
Gone are the days when patients with cancer were, for the most part, protected from healthcare costs by their medical insurance. According to a recent study sponsored by the National Comprehensive Cancer Network and conducted by Ronan J. Kelly, MD, MBA, MBBCh, Assistant Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, and colleagues, with high deductibles, escalating copayments, and cost-sharing requirements becoming the status quo, patients with cancer are now, more than ever, feeling the effects of financial toxicity, particularly young patients who are especially susceptible to filing for medical bankruptcy (Kelly RJ, et al.
J Oncol Pract
. 2015;11:308-312).
Read Article
Assessing the Cost-Effectiveness of Necitumumab in Squamous-Cell Lung Cancer
By
Dana Taylor
Economics & Value
,
Economics of Cancer Care
August 2015, Vol 6, No 7
Chicago, IL—An economic analysis presented by Daniel Goldstein, MD, of Emory University, Atlanta, GA, at the 2015 American Society of Clinical Oncology meeting, was conducted to see at what price will necitumumab (which is currently being reviewed by the FDA for use in metastatic squamous-cell lung cancer) be cost-effective. According to this analysis, necitumumab will have to be priced at less than $1300 per cycle to be cost-effective based on the accepted willingness-to-pay threshold of $150,000.
Read Article
Site of Service Significantly Impacts Cost of Chemotherapy
By
Dana Taylor
Economics & Value
,
Economics of Cancer Care
August 2015, Vol 6, No 7
Chicago, IL—An analysis of chemotherapy infusion by Aetna shows that approximately 75% of their patients still receive chemotherapy in a community oncology setting, suggested Michael A. Kolodziej, MD, National Medical Director for Oncology Strategy, Aetna at the 2015 American Society of Clinical Oncology meeting.
Read Article
Dissecting the Cost of Targeted Therapies in Oncology
By
Dana Taylor
Economics & Value
,
Economics of Cancer Care
,
Targeted Therapy
August 2015, Vol 6, No 7
Chicago, IL—It is not a surprise that targeted therapies are the main drivers of spending on anticancer drugs in the United States. At the 2015 American Society of Clinical Oncology meeting, researchers presented data from several major cancer centers about the cost of targeted therapies.
Read Article
The New PC-SAF Instrument: A Patient-Reported Outcome Tool for Identifying the Symptoms of Pancreatic Cancer
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
June 2015, Vol 6, No 5
Philadelphia, PA—The prognosis for patients with pancreatic cancer, the leading cause of cancer-related deaths in the United States, remains poor. The diagnosis of pancreatic cancer is often delayed to a late stage, which affects impact. Improving the understanding of the early signs and symptoms of this cancer may improve outcomes.
Read Article
Increasing Use of Value Analysis Committees in US Hospitals: Implications for Healthcare Providers and Manufacturers
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
June 2015, Vol 6, No 5
Philadelphia, PA—The growing focus on identifying and preventing overpayments and reducing waste in the healthcare system has prompted hospitals to adopt value analysis committees to curb unnecessary medical supply spending. In 2012, as many as 64% of US hospitals were using a value analysis committee to evaluate new devices and new supplies used in their institutions.
Read Article
Health Plan Cost-Savings with Netupitant/Palonosetron for the Prevention of CINV
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
May 2015, Vol 6, No 4
San Diego, CA—According to the National Comprehensive Cancer Network guidelines for the prevention of chemotherapy-induced nausea and vomiting (CINV), highly and moderately emetogenic chemotherapy should be managed with a 5-HT3 receptor antagonist, an NK1 receptor antagonist, and dexamethasone (Decadron).
Read Article
Real-World Treatment Patterns of Axitinib for Advanced Renal-Cell Carcinoma
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
May 2015, Vol 6, No 4
San Diego, CA—Approved in 2012 by the FDA, axitinib (Inlyta) is indicated for the treatment of patients with advanced renal-cell carcinoma (RCC) whose disease had failed 1 previous systemic therapy. The approval of axitinib was based on the safety and efficacy data from clinical trials, which are often limited in their patient population and short-term analysis.
Read Article
Page 1 of 9
1
2
3
4
5
6
7
8
9
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma